Interview with CEO and Co-Founder of Repair Biotechnologies, Reason

Repair Biotechnologies is a Syracuse based late preclinical-stage biotech company developing first-in-class therapies based on its proprietary Cholesterol Degrading Platform.  Repair Biotechnologies’ drug candidate, REP-0001, is an enzyme-based drug that converts cholesterol into a water-soluble compound that can be excreted in the urine. It is a novel, highly effective, and very well-tolerated treatment for atherosclerosis,  the world's number one killer, responsible for the best-selling drugs of all time (e.g. Lipitor at $150B in sales). Repair Biotechnologies’ initial pathway to the clinic will be through homozygous familial hypercholesterolemia (HoFH), an orphan indication. HoFH is a genetic disorder characterized by two defective copies of the LDLR gene. These patients have an extremely accelerated form of atherosclerosis.